Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01489345 · ClinicalTrials.gov registry record · Phase 1

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

A Phase 1 study of Healthy, sponsored by Ono Pharma USA.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT01489345 is a Phase 1 study of Healthy that has completed, run by Ono Pharma USA. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01489345, a Phase 1 study of Healthy, has completed, sponsored by Ono Pharma USA.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.

Conditions Studied

Interventions

  • DRUG ONO-2952
  • DRUG ONO-2952 Matching Placebo

Study Locations (1)

Texas

  • Austin Clinical Site - Austin

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2011-12
Phase Phase 1

Sponsor

Ono Pharma USA

17 total trials

What the Registry Record Tells You About NCT01489345

The ClinicalTrials.gov registry entry for NCT01489345 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which ONO-2952 is the first listed.

NCT01489345 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01489345 about?

NCT01489345 is a clinical study titled "Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects". The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.

What is the current status of trial NCT01489345?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-12.

What conditions does trial NCT01489345 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01489345?

The interventions under investigation include: ONO-2952 (DRUG), ONO-2952 Matching Placebo (DRUG).

Who is sponsoring clinical trial NCT01489345?

This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01489345 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.